Publication
Title
Caelyx™ in malignant mesothelioma : a phase II EORTC study
Author
Abstract
Background: The use of doxorubicin has shown some activity in malignant mesothelioma but prolonged administration is hampered by cardiotoxicity. Caelyx(TM), a new liposomal and pegylated form of doxorubicin has shown a better pharmacokinetic and toxic profile then doxorubicin. In a phase II study, the efficacy and toxicity of Caelyx(TM) was tested in previously untreated patients with malignant pleural mesothelioma. Patients and methods: Thirty-three patients who had measurable or evaluable histologically confirmed malignant pleural mesothelioma were included in the study. Caelyx(TM) (45 mg/m(2)) was given i.v. on outpatient base every four weeks for nine cycles or till progression or unacceptable toxicity occurred. Results: Of the 33 patients, 32 were evaluable for toxicity and 31 for response. Two patients had a partial response (6%, 95% confidence interval: 0.2%-20.2%). The median survival was 13 months. Forty percent of the patients received > 6 cycles. Toxicity was mild with palmar plantar erythrodysesthesia being most pronounced (62% grade 1-2, 6% grade 3) and of limited duration. Ten percent of patients had grade 3 anemia and 3% grade 3 thrombocytopenia. Two patients (6%) had grade 3 or 4 cardiac toxicity, which was not drug related. Conclusion: At the prescribed dose, single agent Caelyx(TM) is well tolerated but its activity in chemotherapy-naive mesothelioma patients does not warrant further investigation as a single agent.
Language
English
Source (journal)
Annals of oncology / European Society for Medical Oncology. - Amsterdam
Publication
Amsterdam : 2000
ISSN
0923-7534
Volume/pages
11:6(2000), p. 697-700
ISI
000088219600015
Full text (Publisher's DOI)
Full text (publisher's version - intranet only)
UAntwerpen
Faculty/Department
Publication type
Subject
External links
Web of Science
Record
Identification
Creation 18.11.2014
Last edited 08.08.2017